64 results about "Neuraminidase activity" patented technology

This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activity comprising a sialylated oligosaccharide and N-acetyl-lactosamine and / or an oligosaccharide containing N-acetyl-lactosamine The invention further extends to the use of such a composition in the prevention of secondary infections such as otitis media.

The invention relates to a test paper tape which can be used in the gynecological multiprogramming dry-chemistry joint detection. The test paper tape provided by the utility model comprises a dry-chemistry multiprogramming detection test paper tape which consists of a plastic substrate tape and various solidified regent blocks, and sample diluent. The dry regent blocks include combinations formed by increasing or decreasing at least three or more regent blocks of a Ph test regent block, a lactic acid regent block, a hydrogen peroxide concentration regent block, a leukocyte esterase concentration regent block, a neuraminidase activity regent block, an amine test regent block, a proline aminopeptidase substrate reagent block, an oxidase substrate reagent block, a N-acetylamine hexosidase substrate reagent block, a trichomonas specific protease substrate hydrolysis reagent block. the gynecological multiprogramming dry-chemistry joint detection test paper test provided by the utility model can detect Ph, lactic acid, hydrogen peroxide, leukocyte esterase, neuraminidase, amine test, proline aminopeptidase, oxidase, N-acetylamine hexosidase and trichomonas specific protease which are contained in leucorrhea sample at the same time, and can accurately reflect the microorganism environment of a women reproductive tract, the cleanness of leucorrhea secretion and the conditions of Candida albicans, trichomonas, gonococcus and the pathogens of bacterial vaginosis, thereby making the gynecological trichomonas detection more comprehensive; besides, the test paper tape provided by the utility model can be used easily and conveniently, and results can be obtained quickly. If the test paper tape is used together with a gynecological dry-chemistry analyzer, the operation can become easier and the result can be obtained more quickly.

The invention belongs to the field of marine medicines, and relates to a fucosan sulphate, a preparation method thereof and application of the fucosan sulphate in preparing an anti-influenza virus medicine. Polysaccharide with a main chain taking alpha-1,2-D-mannose and beta-1,4-D-glucuronic acid as repetitive units, and with a branched chain of alpha-1,3-L-fucosan sulphate is obtained by virtue of hot-water extraction, calcium chloride precipitation and DEAE-Cellulose chromatographic column purification. The fucosan sulphate prepared by the invention is high in inhibition effect on the influenza virus neuraminidase activities of A H1N1, H5N1 and H3N2, and obvious in protection effect on the dog kidney epithelial cells infected by A H1N1. The fucosan sulphate provided by the invention has the advantages of being rich in raw material source, simple in preparation process, easy to industrialize, high in product water solubility, high in stability, free from toxic and side effects, and the like, and has the prospect of being developed to the anti-influenza virus medicine.

Disclosed is a composition comprising a turmeric extract for preventing and treating influenza virus infection and for inhibiting neuraminidase activity. A turmeric extract, its fraction, and a curcuminoid-based compound separated therefrom may inhibit neuraminidase activity and have antiviral and cell degeneration inhibitory effects on influenza virus, and may be useful in preventing and treating influenza virus infection.

The invention provides a method for detecting neuraminidase influencing sperm functions. The method is a novel laboratory detecting method for assessing quality and functions of a sperm and can provide detection and clinical consultations for male infertility patients without clear clinical reasons for infertility. The method is characterized in that expressions of neuraminidase in the sperm are visually quantized through single sperm fluorescence strength analysis or are visually observed by means of fluorescence imaging under a microscope, and if the neuraminidase is highly expressed in the sperm, capacitation of the sperm is achieved through external capacitation liquid, and neuraminidase activity is detected in a fluorescence method.

The invention discloses cyclohexene compounds and an application thereof, and belongs to the field of medicinal chemistry. The cyclohexene compounds are cyclohexene compounds having a structure characteristic represented by the formula I and pharmaceutically acceptable salts and ester prodrugs or stereoisomers thereof; the cyclohexene compounds are subjected to influenza virus neuraminidase activity detection and are confirmed to have good inhibition activity on both wild type and drug-resistant mutant type influenza viruses; a part of the compounds have the inhibition activity IC50 on the wild type and drug-resistant mutant type influenza virus neuraminidase of less than 5 nM, and have the effect for significantly inhibiting the influenza viruses; the cyclohexene compounds or the pharmaceutically acceptable salts or the stereoisomers thereof are showed to have a good application prospect in preparation of anti-influenza virus drugs, thereby providing a new drug choice for clinic treatment of influenza.

A chemiluminescent system for detecting the presence of influenza virus in a biological fluid sample is provided. An influenza diagnostic kit is provided which includes (1) a sampling device for obtaining the biological fluid from a subject, (2) a chemiluminescent substrate material which, in the presence of influenza virus in the biological sample, will generate a chemiluminescent product that will produce detectable light, and (3) a means for detecting any generated light. A liquid sample containing the biological fluid, and preferably a diluent, are contacted with the an absorbent material containing the chemiluminescent substrate material. The substrate responds to neuraminidase activity intrinsic to influenza A and influenza B virus particles, such that when the substrate is in contact with influenza virus, the substrate is cleaved to yield a chemiluminescent product that then decomposes to produce light which can then be detected. The chemiluminescent substrate materials include enzymatically triggerable 1,2-dioxetane derivatives of 4-alkoxy-N-acetylneuraminic acid and 4,7-dialkoxy-N-acetyineuraminic acid. The system is sufficiently simple that it can reliably be used by a layperson in a nonmedical setting. The biological fluid generally originates from the oral cavity, the pharyngeal cavity, or the nasopharyngeal cavity.

The invention relates to a baicalin injection with anti-influenza virus effect, which is prepared from baicalin weighed according to required volume and set concentration, 0.6g of sodium dihydrogen phosphate, 2.16g of disodium hydrogen phosphate and 100ml of injection water through high-temperature high-pressure sterilization, wherein the pH value of sodium hydroxide is regulated to 7.0. The medicine has a remarkable advantages of in-vivo and in-vitro anti-influenza virus activity, high bioavailability, small side effect and adverse response and the like, has the effect of inhibiting neuraminidase activity to stop virus release, has unique advantages and wide development prospect in the field of preventing and treating influenza virus.

The invention relates to the technical field of biological medicines. The invention relates to a benzocoumarin chalcone neuraminidase inhibitor and a preparation method and application thereof, and the inhibitor has a structure shown as a formula I. The compound is novel in structure, and experiments show that the compound has good neuraminidase inhibition activity and is expected to be used for preparing medicines for inhibiting neuraminidase activity.

The invention discloses application of neuraminidase and neuraminidase inhibitors to preparation of medicines for inhibiting hepatic gluconeogenesis. Zanamivir and oseltamivir phosphate are effectiveinhibitors of the neuraminidase; the inhibition effect of coptisine on neuraminidase is also disclosed in the previous patent application of the applicant. The applicant also discovers that salvanic acid B is capable of inhibiting the activity of the neuraminidase in vitro and is used as an inhibitor of the neuraminidase. In-vivo test proves that the several neuraminidase inhibitors are capable ofeffectively inhibiting the activity of the neuraminidase in the liver and then inhibiting hepatic gluconeogenesis. Therefore, the neuraminidase and the neuraminidase inhibitors can be used for preparing the medicines for inhibiting hepatic gluconeogenesis and can also be used for treating diabetes, obesity and non-alcoholic fatty liver disease.

The present invention relates to a composition for suppressing neuraminidase activity comprising a geranylated flavonoid derived from Paulownia tomentosa as an active ingredient. The Paulownia tomentosa extract and the geranylated flavonoid isolated therefrom exhibit an effect in significantly suppressing neuraminidase, which is an enzyme that plays an important role in the occurrence of pathogenic viral and bacterial infections and of the inflammation that accompanies such infection, and thus the Paulownia tomentosa extract or the geranylated flavonoid isolated therefrom can advantageously be used as an active ingredient in a composition for suppressing neuraminidase activity.

The invention relates to a 1, 3, 4-oxadiazole neuraminidase inhibitor as well as a preparation method and an application thereof. The inhibitor has a structure as shown in a formula (I). The preparation method specifically comprises the following steps: (1) reacting aniline, chloroacetyl chloride and triethylamine, and performing post-treatment to obtain an intermediate as shown in a formula (II); (2) performing reaction on benzoyl hydrazine, carbon disulfide and potassium hydroxide, and performing post-treatment to obtain an intermediate as shown in a formula (III); and (3) dissolving the intermediate shown in the formula (II) and the intermediate shown in the formula (III) in an organic solvent, reacting, and performing post-treatment to obtain the inhibitor shown in the formula (I). Compared with the prior art, the compound is novel in structure, and experiments show that the compound has good neuraminidase inhibitory activity and can be used for preparing drugs for inhibiting neuraminidase activity.

The invention discloses a living lung slicing based anti-influenza virus or anti-inflammatory drug screening model establishing method and application. The method is characterized by including the following steps of firstly, slicing the virus-infected living lung; secondly, allowing to-be-detected drugs to act on slices of the virus-infected living lung; finally, verifying effect of the to-be-detected drugs by detecting changes of virus titer and related cytokines. The invention further discloses a screening model establishing method which includes: preparation of the lung slices, optimal thickness selection of the lung slices, relevant evaluation of neuraminidase and the virus titer and selection of inflammatory factors. The drug screening method on the basis of living lung slicing is established, and compared with a traditional cell model, the living lung slicing based anti-influenza virus or anti-inflammatory drug screening model establishing method is more in line with true body conditions and is more effective in accuracy.

The invention discloses an anti-avian influenza virus neuraminidase N2 monoclonal antibody and encoding engine and application thereof, and belongs to the technical field of biomedicine. The anti-avian influenza virus neuraminidase N2 monoclonal antibody specifically identifies avian influenza virus neuraminidase protein N2, and has the ability to inhibit neuraminidase activity and neutralize virus. According to the anti-avian influenza virus neuraminidase N2 monoclonal antibody and encoding engine and application thereof, the gene sequence and the amino acid sequence of light-heavy chain variable region of the anti-avian influenza virus neuraminidase N2 monoclonal antibody are further cloned, and the uniqueness of the gene sequence and the amino acid sequence is confirmed. The related monoclonal antibody and the variable region gene and amino acid sequence can be used for diagnosis, therapeutic development and the like of the N2 avian influenza virus, and have wide clinical application value.

The invention discloses an application of tiliroside in preparation of an anti-influenza drug. Prevention and treatment effects on influenza viruses are achieved by inhibiting neuraminidase activity.The invention provides a novel neuraminidase inhibitor, namely tiliroside, from a natural product duchesnea indica extract. The tiliroside can inhibit neuraminidase of influenza virus oseltamivir sensitive strains and drug-resistant strains, makes up for defects in the prior art, and is expected to be popularized and used as a novel neuraminidase inhibitor anti-influenza drug.

The invention relates to a thiazolidine neuraminidase inhibitor and application thereof. The thiazolidine neuraminidase inhibitor is a compound shown as a formula I and a mixture of an optical isomer, a diastereoisomer and raceme of the compound. The application of the compound shown as the formula I in preparing medicines for preventing or treating diseases related to the activity of neuraminidase is disclosed.

Disclosed is a composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides as active ingredients, and the ginseng berry polysaccharides exhibit an inhibitory effect on influenza virus activity or infection due to specific ingredients and structures and, specifically, have an excellent inhibitory effect on neuraminidase activity.

Novel paramyxovirus hemagglutinin-neuraminidase active site and methods for enabling the design and selection of inhibitors with that active site are provided. Also provided is machine-readable data storage medium comprising structure coordinates of the novel paramyxovirus hemagglutinin-neuraminidase active site.

The present invention relates to: a protein which does not have a neuraminidase activity substantially and has a beta-galactoside-alpha 2,3-sialyltransferase activity; a nucleic acid which encodes the enzyme protein; and a process for producing the enzyme using a microorganism transformed with a gene encoding the protein. This protein is a modified enzyme protein produced by mutating a specific amino acid residue in a beta-galactoside-alpha 2,3-sialyltransferase protein derived from a microorganism belonging to the family Vibrio, the genus Photobacterium to substantially inactive the neuraminidase activity of the protein.

The invention discloses an anti-influenza virus or anti-inflammatory drug screening model based on living lung slices, which is characterized in that it comprises the following steps: first infecting the living lung slices with the virus, and then applying the drug to be tested to the virus-infected Live lung slices, and finally verify the effect of the drug to be tested by detecting changes in virus titers and related cytokines. The invention also discloses a method for constructing the screening model, which includes: preparation of lung slices, optimization of thickness of lung slices, evaluation of the correlation between neuraminidase activity and virus titer, and selection of inflammatory factors. Through this invention, a drug screening method based on living lung slices is constructed, which is more accurate and effective than traditional cell models in line with real body conditions.

The invention relates to a 2-aminothiophene neuraminidase inhibitor, preparation and application thereof, wherein the structural formula of the inhibitor is shown in the specification. The preparation method specifically comprises the following steps: (1) carrying out reaction on methyl acetoacetate, sublimed sulfur and ethyl cyanoacetate, and then carrying out post-treatment to obtain an intermediate shown in a formula (II); (2) dissolving the intermediate in the formula (II) in an organic solvent, and reacting with chloroacetyl chloride to obtain an intermediate in a formula (III) after the reaction; and (3) dissolving the intermediate shown in the formula (III) and substituted aromatic phenol in an organic solvent, reacting, and performing post-treatment to obtain the inhibitor shown in the formula (I). Compared with the prior art, the compound of the invention is novel in structure, and experiments show that the compound has good neuraminidase inhibitory activity and can be used for preparing drugs for inhibiting neuraminidase activity.

The invention discloses application of neuraminidase and an inhibitor in preparing a medicine for treating pulmonary fibrosis and renal fibrosis. Reports show that zanamivir and oseltamivir phosphateare effective inhibitors of neuraminidase, the inhibition functions of coptisine to neuraminidase are also already disclosed in former patents of the inventor, and the inventor also finds that danshinolic acid B is capable of inhibiting activity of neuraminidase in vitro and is a neuraminidase inhibitor; tests show that the neuraminidase inhibitors are capable of effectively inhibiting activity ofneuraminidase in lung and kidney tissue, and furthermore pulmonary fibrosis and renal fibrosis can be inhibited. Therefore, neuraminidase and inhibitors thereof can be adopted to prepare medicines for treating pulmonary fibrosis and renal fibrosis.

The invention discloses the application of neuraminidase and an inhibitor to preparation of medicines for treating hypertension. The known zanamivir and oseltamivir phosphate are effective inhibitorsof the neuraminidase, the inhibition effect of coptisine on the neuraminidase is disclosed in the previous patent application of an applicant, and the applicant finds that danshinolic acid B can inhibit the activity of the neuraminidase in vitro and is the inhibitor of the neuraminidase; in-vivo experiments prove that the neuraminidase inhibitors can effectively inhibit the activity of the neuraminidase of vascular endothelial cells so as to reduce blood pressure. Therefore, the neuraminidase and the inhibitor thereof can be applied to preparation of the medicines for treating hypertension.

The invention relates to an oxamide neuraminidase inhibitor and preparation and application thereof. The structural formula of the inhibitor is shown in the specification. The preparation method specifically comprises the following steps of: (1) forming a reaction system from substituted aniline, oxalyl chloride monoethyl ester, triethylamine and ethyl acetate, and performing post-treatment after reaction to obtain an intermediate shown in a formula (II); (2) dissolving the intermediate in the formula (II) in an organic solvent, adding potassium hydroxide to form a reaction system, and reacting to obtain an intermediate in a formula (III); and (3) dissolving the intermediate shown in the formula (III) in an organic solvent, adding 1-hydroxybenzotriazole (HOBt) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) to form a reaction system, and carrying out post-treatment after the reaction to obtain the inhibitor shown in the formula (I). The compound is novel in structure, and experiments show that the compound has good neuraminidase inhibitory activity and can be used for preparing drugs for inhibiting neuraminidase activity.

The invention discloses an application of neuraminidase and inhibitors thereof in preparation of drugs for treating myocardial fibrosis and ventricular hypertrophy. Zanamivir and oseltamivir phosphateare known as effective inhibitors of neuraminidase, and an inhibitory effect of coptisine on neuraminidase also is published in an applicant previous patent application; salvianolic acid B is also found to be able to inhibit the activity of neuraminidase in vitro, and is a neuraminidase inhibitor; experiments prove that the multiple kinds of neuraminidase inhibitors can effectively inhibit the activity of neuraminidase in myocardium in vivo, then inhibit myocardial fibrosis and ventricular hypertrophy, and can be used for treating heart disease caused by myocardial fibrosis and ventricular hypertrophy. Therefore, neuraminidase and the inhibitors thereof can be used for preparation of the drugs for treating myocardial fibrosis and ventricular hypertrophy.

The invention relates to a coumarin 3-formamide neuraminidase inhibitor as well as preparation and an application thereof. The inhibitor has a structure as shown in a formula (I). The preparation method specifically comprises the following steps: (1) reacting salicylaldehyde and diethyl malonate, and performing post-treatment to obtain an intermediate as shown in a formula (II); and (2) dissolving the intermediate in the formula (II) and substituted aniline in an organic solvent, reacting, and performing post-treatment to obtain the inhibitor as shown in the formula (I). The compound is novel in structure, and experimental results show that the compound has good neuraminidase inhibitory activity and can be used for preparing drugs for inhibiting neuraminidase activity.

The invention discloses application of neuraminidase and inhibitors in preparing anti-thrombotic medicine. As known, zanamivir and oseltamivir phosphate are effective inhibitors of the neuraminidase,an inhibition effect of coptisine on the neuraminidase also has been disclosed in precious patent application of an applicant, and the applicant also proves that salvianolic acid B is capable of inhibiting the activity of the neuraminidase in vitro and is the inhibitor of the neuraminidase; an in-vivo experiment proves that the inhibitors of the neuraminidase are capable of effectively inhibitingthe activity of the neuraminidase in vascular endothelial cells and playing an anti-thrombotic effect; as a consequence, the neuraminidase and the inhibitors thereof can be used for preparing the anti-thrombotic medicine and can be used for treating cerebral apoplexy or coronary heart disease.